[1]闫霞,曹官铭,王导新.吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913-1915.
 YAN Xia,CAO Guan-min,WANG Dao-xin.Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients[J].J Third Mil Med Univ,2007,29(19):1913-1915.
点击复制

吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
29卷
期数:
2007年第19期
页码:
1913-1915
栏目:
论著
出版日期:
2007-10-15

文章信息/Info

Title:
Gemcitabine plus carboplatin regimen in treatment of advanced non-small cell lung cancer in aged patients
作者:
闫霞曹官铭王导新
重庆市第四人民医院呼吸内科;重庆医科大学附属第二医院呼吸内科
Author(s):
YAN Xia CAO Guan-min WANG Dao-xin
Department of Respiratory Disease,  the Fourth People’s Hospital of Chongqing, Chongqing 400014, China
关键词:
非小细胞肺癌吉西他滨老年化疗
Keywords:
non-small cell lung cancerold agedrug therapygemcitabine
分类号:
R730.53; R734.2; R979.12
文献标志码:
A
摘要:
目的  观察吉西他滨(gemcitabine,GEM)联合卡铂(carboplatin,CBP)在晚期老年非小细胞肺癌临床疗效及毒性反应。  方法  60例晚期老年(≥65岁)非小细胞肺癌分成吉西他滨组(A组)和长春瑞滨组(B组),A组:吉西他滨+卡铂(30例),B组:长春瑞滨+顺铂(30例)。吉西他滨1 000 mg/ m2 ,第1、8天, 卡铂300 mg/m2, 第1天,每3周为1个周期;长春瑞滨25 mg/ m2,第1、8天, 顺铂80 mg/m2,第1、3天,每3周为1个周期。  结果  60例患者的症状均有不同程度的改善。A组及B组有效率为43.3%及36.7%,两组间无显著性差异(P>0.05)。中位生存期(median survival time, MST)、疾病缓解时间(disease median response  time, DPT)A组及B组分别为9.2个月、8.9个月及4.4个月、4.2个月。1年生存率A组及B组分别为455%、41.6%。两组间无显著性差异(P>0.05)。毒性反应:B组白细胞Ⅲ/Ⅳ度下降发生率和静脉炎的发生率明显高于A组(P<0.05)。  结论  吉西他滨+卡铂与长春瑞滨+顺铂对晚期老年非小细胞肺癌的近期临床疗效相近,MST、DTP、1年生存率均相似,但吉西他滨组耐受性及毒性反应低于长春瑞滨组。吉西他滨联合卡铂方案可作为治疗晚期老年非小细胞肺癌有效的化疗方案。
Abstract:
Objective    To evaluate and the effects and safety of gemcitabine plus carboplatin (GEM+CBP) regimen and navebine plus cisplatin (NVB+DDP) regimens for aged patients with advanced non-small cell lung cancer (NSCLC).     Methods    The 60 cases of aged patients with NSCLC, over 65 years old and 35 cases beyond 70, were randomly and equally divided into 2 groups. Group A received 1 000 mg/m2 GEM at day 1 and 8, and 300 mg/m2 CBP at day 1. Group B underwent the therapy of 25 mg/ m2 NVB at day 1 and 8, and 80 mg/m2 DDP at day 1 and 3. Both were treated with 3 weeks as a cycle.     Results    Overall response rate was 43.3% in group A and 36.7% in group B without significant difference. The median survival time (MST) and disease median response  time(DPT) was 9.2 and 4.4 months in A group, and 8.9 and 4.2 months in B group. MST, DPT and one year survival rate were similar in 2 groups. Toxicities: WHO grade Ⅲ/Ⅳ leukopenia occurred in  B group  was  higher than that in  A group. The frequence of phlebitis was significantly higher in group  B than group A (P<0.05).     Conclusion    There are similar outcomes in the overall response rates, MST, DRT and one year survival rate in 2 groups, but GEM+CBP regimen has a better tolerability and lower toxicities. GEM+CBP regimen is a better  chemotherapeutic regimen for aged NSCLC patients.

参考文献/References:

闫霞,曹官铭,王导新.  吉西他滨联合卡铂治疗老年非小细胞肺癌的临床评价[J].第三军医大学学报,2007,29(19):1913-1915.

相似文献/References:

[1]蒋娟,易亭伍,张瑜,等.非小细胞肺癌的肿瘤干细胞与非肿瘤干细胞中表皮生长因子受体基因异质性的研究[J].第三军医大学学报,2012,34(20):2039.
 Jiang Juan,Yi Tingwu,Zhang Yu,et al.Genetic heterogeneity of EGFR in cancer and non-cancer stem cells from non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(19):2039.
[2]杨庆羚,刘翩,王斌,等.EGFR-TKIs治疗晚期非小细胞肺癌并发间质性肺炎4例报告并文献复习[J].第三军医大学学报,2012,34(20):2060.
 Yang Qingling,Liu Pian,Wang Bin,et al.Interstitial pneumonia in EGFR-TKIs-treated non-small-cell lung cancer: report of 4 cases and review of the literature[J].J Third Mil Med Univ,2012,34(19):2060.
[3]斯晓燕,张力.西妥昔单抗联合化疗一线治疗非小细胞肺癌20例临床观察[J].第三军医大学学报,2012,34(20):2063.
 Si Xiaoyan,Zhang Li.Outcomes of cetuximab combined with chemotherapy as first line therapy in 20 patients with non-small cell lung cancer[J].J Third Mil Med Univ,2012,34(19):2063.
[4]罗虎,罗丹,宫亮,等.联合CIK细胞与化疗对比单纯化疗治疗中晚期非小细胞肺癌的Meta分析[J].第三军医大学学报,2012,34(20):2119.
[5]张瑞萍,吴继华,黄英武,等.循环肿瘤细胞检测指导老年非小细胞肺癌个体化治疗1例[J].第三军医大学学报,2012,34(22):2248.
[6]闵发胜,陈正堂.人非小细胞肺癌与外周血淋巴细胞表达LRP的相关性研究[J].第三军医大学学报,2007,29(17):1699.
 MIN Fa-sheng,CHEN Zheng-tang.Correlation between expression of lung resistance-related protein in non-small cell lung cancer and that in peripheral blood lymphocytes[J].J Third Mil Med Univ,2007,29(19):1699.
[7]高娟,饶进军,吴少瑜,等.丁酸钠与顺铂联用对非小细胞性肺癌细胞生长的抑制作用[J].第三军医大学学报,2007,29(11):1066.
 GAO Juan,RAO Jin-jun,WU Shao-yu,et al.Combination of sodium butyrate and cisplatin has antiproliferative effects on non-small lung cancer cell line[J].J Third Mil Med Univ,2007,29(19):1066.
[8]郑顺利,杨庆生,马小红.非小细胞肺癌患者纵隔淋巴结和外周血中MUC1基因的检测及意义[J].第三军医大学学报,2006,28(24):2472.
[9]张云嵩,范士志,王东,等.APE1在非小细胞肺癌中的表达特点及其与预后的关系[J].第三军医大学学报,2007,29(09):776.
 ZHANG Yun-song,FAN Shi-zhi,WANG Dong,et al.APE1 expression and its correlation with prognosis in non-small cell lung cancer[J].J Third Mil Med Univ,2007,29(19):776.
[10]徐小杰,梅同华.非小细胞肺癌组织中KAI1/CD82基因表达及意义[J].第三军医大学学报,2006,28(13):1443.
[11]王言.吉西他滨联合顺铂方案治疗局部晚期非小细胞肺癌近期疗效观察[J].第三军医大学学报,2009,31(07):588.
[12]张明慧,胡义德,仲晨.含顺铂的4组联合化疗方案治疗晚期非小细胞肺癌的临床疗效比较[J].第三军医大学学报,2009,31(08):744.
 ZHANG Ming-hui,HU Yi-de,ZHONG Chen.Therapeutic effects of 4 cisplatin-based regimens for advanced non-small cell lung cancer: report of 166 cases[J].J Third Mil Med Univ,2009,31(19):744.
[13]刘国祥,杨和平,熊玮,等.GP方案治疗50例晚期非小细胞肺癌的疗效观察[J].第三军医大学学报,2003,25(18):0.[doi:10.16016/j.1000-5404.2003.18.027 ]
 LIU Guo xiang,YANG He ping,XIONG Wei.[J].J Third Mil Med Univ,2003,25(19):0.[doi:10.16016/j.1000-5404.2003.18.027 ]

更新日期/Last Update: 2008-07-15